Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles

Redox Biology

Volumn 11, Issue , 2017, Pages 240-253

  Morry, Jingga ^a   Ngamcherdtrakul, Worapol ^a,b   Yantasee, Wassana ^a,b  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b PDX Pharmaceuticals LLC   (United States)

Author keywords

Antioxidant; Cancer; Fibrosis; Metastasis; Nanoparticles; ROS

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CELASTROL; CERIUM OXIDE NANOPARTICLE; CONNECTIVE TISSUE GROWTH FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOKINE; DIPHENYLIODONIUM SALT; FULLERENE; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; MANGANESE SUPEROXIDE DISMUTASE; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; PLATELET DERIVED GROWTH FACTOR; PLATINUM NANOPARTICLE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RETINOL; SELENIUM; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; FIBROSIS; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HEAD AND NECK CANCER; HUMAN; LIVER FIBROSIS; LUNG CANCER; MALIGNANT NEOPLASM; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; RADIATION DERMATITIS; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TUMOR HYPOXIA; TUMOR VASCULARIZATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; MYOFIBROBLAST; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR INVASION; VASCULARIZATION;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL PROLIFERATION; FIBROBLASTS; FIBROSIS; HUMANS; MYOFIBROBLASTS; NADPH OXIDASES; NANOPARTICLES; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TRANSFORMING GROWTH FACTOR BETA;

EID: 85007409335     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2016.12.011     Document Type: Review

References (179)

1. [1] Brown, D.I., Griendling, K.K., Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ. Res. 116:3 (2015), 531–549.
2. [2] Liou, G.-Y., Storz, P., Reactive oxygen species in cancer. Free Radic. Res., 44(5), 2010, 10.3109/10715761003667554.
3. [3] Liu, Y., Fiskum, G., Schubert, D., Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80:5 (2002), 780–787.
4. [4] Bedard, K., Krause, K.H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87:1 (2007), 245–313.
5. [5] Fang, F.C., Antimicrobial actions of reactive oxygen species. mBio, 2(5), 2011.
6. [6] Rowe, L.A., Degtyareva, N., Doetsch, P.W., Damage-induced, D.N.A., Reactive oxygen species (ROS) stress response in Saccharomyces cerevisiae. Free Radic. Biol. Med. 45:8 (2008), 1167–1177.
7. [7] M.Schieber, N.Chandel, ROS function in redox signaling and oxidative stress, Curr. Biol., 24(10), pp. R453–R462.
8. [8] Waris, G., Ahsan, H., Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog., 5, 2006 14-14.
9. [9] Babalola, O., Mamalis, A., Lev-Tov, H., Jagdeo, J., NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents. Arch. Dermatol. Res. 306:4 (2014), 313–330.
10. [10] Hecker, L., Cheng, J., Thannickal, V.J., Targeting, NOX enzymes in pulmonary fibrosis. Cell Mol. Life Sci. 69:14 (2012), 2365–2371.
11. [11] De Minicis, S., Brenner, D.A., NOX in liver fibrosis. Arch. Biochem. Biophys. 462:2 (2007), 266–272.
12. [12] Holterman, C.E., Read, N.C., Kennedy, C.R., Nox and renal disease. Clin. Sci. (Lond.) 128:8 (2015), 465–481.
13. [13] Roy, K., Wu, Y., Meitzler, J.L., Juhasz, A., Liu, H., Jiang, G., Lu, J., Antony, S., Doroshow, J.H., NADPH oxidases and cancer. Clinical Sci. (Lond.) 128:12 (2015), 863–875.
14. [14] Quintavalle, M., Elia, L., Price, J.H., Heynen-Genel, S., Courtneidge, S.A., A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci. Signal., 4(183), 2011, ra49.
15. [15] Okon, I.S., Zou, M.-H., Mitochondrial, ROS and cancer drug resistance: implications for therapy. Pharmacol. Res. 100 (2015), 170–174.
16. [16] Nishikawa, M., Reactive oxygen species in tumor metastasis. Cancer Lett. 266:1 (2008), 53–59.
17. [17] Olsson, B., Johansson, M., Gabrielsson, J., Bolme, P., Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur. J. Clin. Pharmacol. 34:1 (1988), 77–82.
18. [18] Souto, E.B., Severino, P., Basso, R., Santana, M.H., Encapsulation of antioxidants in gastrointestinal-resistant nanoparticulate carriers. Methods Mol. Biol. (Clifton, N.J.) 1028 (2013), 37–46.
19. [19] Sharpe, E., Andreescu, D., Andreescu, S., Artificial Nanoparticle Antioxidants, Oxidative Stress: Diagnostics, Prevention, and Therapy. 2011, American Chemical Society, Washington, DC, 235–253 http://pubs.acs.org/isbn/9780841226838.
20. [20] Sandhir, R., Yadav, A., Sunkaria, A., Singhal, N., Nano-antioxidants: an emerging strategy for intervention against neurodegenerative conditions. Neurochem. Int. 89 (2015), 209–226.
21. [21] Sosa, V., Moliné, T., Somoza, R., Paciucci, R., Kondoh, H., Lleonart, M.E., Oxidative stress and cancer: an overview. Ageing Res. Rev. 12:1 (2013), 376–390.
22. [22] Richter, K., Konzack, A., Pihlajaniemi, T., Heljasvaara, R., Kietzmann, T., Redox-fibrosis: impact of TGFbeta1 on ROS generators, mediators and functional consequences. Redox Biol. 6 (2015), 344–352.
23. [23] Robinson, J.M., Reactive oxygen species in phagocytic leukocytes. Histochem. Cell Biol. 130:2 (2008), 281–297.
24. [24] Michiels, C., Raes, M., Toussaint, O., Remacle, J., Importance of SE-glutathione peroxidase, catalase, and CU/ZN-SOD for cell survival against oxidative stress. Free Radic. Biol. Med. 17:3 (1994), 235–248.
25. [25] Wynn, T.A., Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Investig. 117:3 (2007), 524–529.
26. [26] J.Varga, D.Abraham, Systemic sclerosis: a prototypic multisystem fibrotic disorder, J. Clin. Investig., 117(3), pp. 557–567.
27. [27] Sebastiani, G., Gkouvatsos, K., Pantopoulos, K., Chronic hepatitis C and liver fibrosis. World J. Gastroenterol.: WJG 20:32 (2014), 11033–11053.
28. [28] Siegmund, S.V., Brenner, D.A., Molecular pathogenesis of alcohol-induced hepatic fibrosis. Alcohol. Clin. Exp. Res. 29:11 Suppl (2005), 102s–109s.
29. [29] Pellicoro, A., Ramachandran, P., Iredale, J.P., Fallowfield, J.A., Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14:3 (2014), 181–194.
30. [30] P.W.Noble, C.E.Barkauskas, D.Jiang, Pulmonary fibrosis: patterns and perpetrators, J. Clin. Investig., 122(8), pp. 2756–2762.
31. [31] Bitterman, P.B., Henke, C.A., Fibroproliferative disorders. Chest 99:3 Suppl (1991), 81s–84s.
32. [32] Li, C., Kuemmerle, J.F., The mechanisms that mediate the development of fibrosis in patients with Crohn's disease. Inflamm. Bowel Dis. 20:7 (2014), 1250–1258.
33. [33] Kendall, R.T., Feghali-Bostwick, C.A., Fibroblasts in fibrosis: novel roles and mediators. Front. Pharmacol., 5, 2014, 123.
34. [34] Pohlers, D., Brenmoehl, J., Löffler, I., Müller, C.K., Leipner, C., Schultze-Mosgau, S., Stallmach, A., Kinne, R.W., Wolf, G., TGF-β and fibrosis in different organs — molecular pathway imprints. Biochim. Biophys. Acta (BBA) – Mol. Basis Dis. 1792:8 (2009), 746–756.
35. [35] Lepparanta, O., Sens, C., Salmenkivi, K., Kinnula, V.L., Keski-Oja, J., Myllarniemi, M., Koli, K., Regulation of TGF-beta storage and activation in the human idiopathic pulmonary fibrosis lung. Cell Tissue Res. 348:3 (2012), 491–503.
36. [36] Dooley, S., ten Dijke, P., TGF-β in progression of liver disease. Cell Tissue Res. 347:1 (2012), 245–256.
37. [37] Kanzler, S., Lohse, A.W., Keil, A., Henninger, J., Dienes, H.P., Schirmacher, P., Rose-John, S., zum Buschenfelde, K.H., Blessing, M., TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am. J. Physiol. 276:4 Pt 1 (1999), G1059–G1068.
38. [38] Corbel, M., Caulet-Maugendre, S., Germain, N., Molet, S., Lagente, V., Boichot, E., Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. J. Pathol. 193:4 (2001), 538–545.
39. [39] Lakos, G., Takagawa, S., Chen, S.J., Ferreira, A.M., Han, G., Masuda, K., Wang, X.J., DiPietro, L.A., Varga, J., Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am. J. Pathol. 165:1 (2004), 203–217.
40. [40] Liu, R.-M., Desai, L.P., Reciprocal regulation of TGF-β and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol. 6 (2015), 565–577.
41. [41] Chan, E.C., Peshavariya, H.M., Liu, G.S., Jiang, F., Lim, S.Y., Dusting, G.J., Nox4 modulates collagen production stimulated by transforming growth factor beta1 in vivo and in vitro. Biochem. Biophys. Res. Commun. 430:3 (2013), 918–925.
42. [42] Nakano, H., Nakajima, A., Sakon-Komazawa, S., Piao, J.H., Xue, X., Okumura, K., Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 13:5 (2006), 730–737.
43. [43] Trachootham, D., Lu, W., Ogasawara, M.A., Valle, N.R.-D., Huang, P., Redox regulation of cell survival. Antioxid. Redox Signal. 10:8 (2008), 1343–1374.
44. [44] U.S. Cancer Statistics Working Group, United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report, 〈www.cdc.gov/uscs〉, 2016.
45. [45] B.W. Stewart, C.P. Wild, World Cancer Report 2014, 2014.
46. [46] Szatrowski, T.P., Nathan, C.F., Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:3 (1991), 794–798.
47. [47] Panieri, E., Santoro, M.M., ROS homeostasis and metabolism: a dangerous liaison in cancer cells. Cell Death Dis., 7, 2016, e2253.
48. [48] Peiris-Pagès, M., Martinez-Outschoorn, Ubaldo E., Sotgia, F., Lisanti, Michael P., Metastasis and oxidative stress: are antioxidants a metabolic driver of progression?. Cell Metab. 22:6 (2015), 956–958.
49. [49] P.Schumacker, Reactive oxygen species in cancer: a dance with the devil, Cancer Cell, 27(2), pp. 156–157.
50. [50] Grimsrud, P.A., Xie, H., Griffin, T.J., Bernlohr, D.A., Oxidative stress and covalent modification of protein with bioactive aldehydes. J. Biol. Chem. 283:32 (2008), 21837–21841.
51. [51] Liu, B., Chen, Y., Clair, D.K. St, ROS and p53: versatile partnership. Free Radic. Biol. Med. 44:8 (2008), 1529–1535.
52. [52] Lim, Y.P., Lim, T.T., Chan, Y.L., Song, A.C., Yeo, B.H., Vojtesek, B., Coomber, D., Rajagopal, G., Lane, D., The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 26:11 (2007), 1517–1521.
53. [53] Rivlin, N., Brosh, R., Oren, M., Rotter, V., Mutations in the p53 Tumor Suppressor Gene: important Milestones at the Various Steps of Tumorigenesis. Genes Cancer 2:4 (2011), 466–474.
54. [54] Trachootham, D., Alexandre, J., Huang, P., Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 8:7 (2009), 579–591.
55. [55] Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., Giaccia, A.J., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:6560 (1996), 88–91.
56. [56] Semenza, G.L., Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33:4 (2012), 207–214.
57. [57] Hsieh, C.-H., Shyu, W.-C., Chiang, C.-Y., Kuo, J.-W., Shen, W.-C., Liu, R.-S., NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS One, 6(9), 2011, e23945.
58. [58] Liu, W., Shen, S.-M., Zhao, X.-Y., Chen, G.-Q., Targeted genes and interacting proteins of hypoxia inducible factor-1. Int. J. Biochem. Mol. Biol. 3:2 (2012), 165–178.
59. [59] Huang, L.E., Arany, Z., Livingston, D.M., Bunn, H.F., Activation of Hypoxia-inducible Transcription Factor Depends Primarily upon Redox-sensitive Stabilization of Its α Subunit. J. Biol. Chem. 271:50 (1996), 32253–32259.
60. [60] Chang, T.-C., Huang, C.-J., Tam, K., Chen, S.-F., Tan, K.T., Tsai, M.-S., Lin, T.-N., Shyue, S.-K., Stabilization of hypoxia-inducible factor-1α by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells. J. Biol. Chem. 280:44 (2005), 36567–36574.
61. [61] Srinivas, V., Leshchinsky, I., Sang, N., King, M.P., Minchenko, A., Caro, J., Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway. J. Biol. Chem. 276:25 (2001), 21995–21998.
62. [62] Hiraga, R., Kato, M., Miyagawa, S., Kamata, T., Nox4-derived, ROS signaling contributes to TGF-beta-induced epithelial-mesenchymal transition in pancreatic cancer cells. Anticancer Res. 33:10 (2013), 4431–4438.
63. [63] Krstic, J., Trivanovic, D., Mojsilovic, S., Santibanez, J.F., Transforming growth factor-beta and oxidative stress interplay: implications in tumorigenesis and cancer progression. Oxid. Med. Cell Longev., 2015, 2015, 654594.
64. [64] Massague, J., TGFbeta in cancer. Cell 134:2 (2008), 215–230.
65. [65] Lebrun, J.-J., The dual role of TGF in human cancer: from tumor suppression to cancer metastasis. ISRN Mol. Biol., 2012, 2012, 28.
66. [66] Gorelik, L., Flavell, R.A., Immune-mediated eradication of tumors through the blockade of transforming growth factor-[beta] signaling in T cells. Nat. Med. 7:10 (2001), 1118–1122.
67. [67] Sakurai, T., Kudo, M., Signaling pathways governing tumor angiogenesis. Oncology 81:Suppl 1 (2011), 24–29.
68. [68] Heldin, C.-H., Vanlandewijck, M., Moustakas, A., Regulation of EMT by TGFβ in cancer. FEBS Lett. 586:14 (2012), 1959–1970.
69. [69] Nakajima, S., Doi, R., Toyoda, E., Tsuji, S., Wada, M., Koizumi, M., Tulachan, S.S., Ito, D., Kami, K., Mori, T., Kawaguchi, Y., Fujimoto, K., Hosotani, R., Imamura, M., N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 10:12 Pt 1 (2004), 4125–4133.
70. [70] Lamouille, S., Xu, J., Derynck, R., Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15:3 (2014), 178–196.
71. [71] Bukholm, I.K., Nesland, J.M., Borresen-Dale, A.L., Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [see comments]. J. Pathol. 190:1 (2000), 15–19.
72. [72] Kase, S., Sugio, K., Yamazaki, K., Okamoto, T., Yano, T., Sugimachi, K., Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 6:12 (2000), 4789–4796.
73. [73] Hermiston, M.L., Wong, M.H., Gordon, J.I., Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev. 10:8 (1996), 985–996.
74. [74] Hazan, R.B., Phillips, G.R., Qiao, R.F., Norton, L., Aaronson, S.A., Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 148:4 (2000), 779–790.
75. [75] Shimada, K., Fujii, T., Anai, S., Fujimoto, K., Konishi, N., ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder. BMC Urol. 11:1 (2011), 1–12.
76. [76] Tobar, N., Guerrero, J., Smith, P.C., Martinez, J., NOX4-dependent ROS production by stromal mammary cells modulates epithelial MCF-7 cell migration. Br. J. Cancer, 103(7), 2010 1040-7.
77. [77] Seo, J.M., Park, S., Kim, J.H., Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2. J. Biol. Chem. 287:17 (2012), 13840–13849.
78. [78] G.P.Gupta, J.Massagué, Cancer Metastasis: Building a Framework, Cell, 127(4), pp. 679–695.
79. [79] Nelson, K.K., Melendez, J.A., Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med. 37:6 (2004), 768–784.
80. [80] Diaz, B., Shani, G., Pass, I., Anderson, D., Quintavalle, M., Courtneidge, S.A., Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci. Signal., 2(88), 2009, ra53.
81. [81] Vaquero, E.C., Edderkaoui, M., Pandol, S.J., Gukovsky, I., Gukovskaya, A.S., Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J. Biol. Chem. 279:33 (2004), 34643–34654.
82. [82] Geiszt, M., NADPH oxidases: new kids on the block. Cardiovasc. Res. 71:2 (2006), 289–299.
83. [83] Diaz, B., Courtneidge, S.A., Redox signaling at invasive microdomains in cancer cells. Free Radic. Biol. Med. 52:2 (2012), 247–256.
84. [84] Block, K., Gorin, Y., Aiding and abetting roles of NOX oxidases in cellular transformation. Nat. Rev. Cancer 12:9 (2012), 627–637.
85. [85] Lambeth, J.D., Kawahara, T., Diebold, B., Regulation of Nox and Duox enzymatic activity and expression. Free Radic. Biol. Med. 43:3 (2007), 319–331.
86. [86] Amara, N., Goven, D., Prost, F., Muloway, R., Crestani, B., Boczkowski, J., NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 65:8 (2010), 733–738.
87. [87] Spadoni, T., Svegliati Baroni, S., Amico, D., Albani, L., Moroncini, G., Avvedimento, E.V., Gabrielli, A., A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol. 67:6 (2015), 1611–1622.
88. [88] Aoyama, T., Paik, Y.H., Watanabe, S., Laleu, B., Gaggini, F., Fioraso-Cartier, L., Molango, S., Heitz, F., Merlot, C., Szyndralewiez, C., Page, P., Brenner, D.A., Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology (Baltimore Md. ) 56:6 (2012), 2316–2327.
89. [89] Jarman, E.R., Khambata, V.S., Cope, C., Jones, P., Roger, J., Ye, L.Y., Duggan, N., Head, D., Pearce, A., Press, N.J., Bellenie, B., Sohal, B., Jarai, G., An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model. Am. J. Respir. Cell Mol. Biol. 50:1 (2014), 158–169.
90. [90] Hecker, L., Vittal, R., Jones, T., Jagirdar, R., Luckhardt, T.R., Horowitz, J.C., Pennathur, S., Martinez, F.J., Thannickal, V.J., NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 15:9 (2009), 1077–1081.
91. [91] Sedeek, M., Callera, G., Montezano, A., Gutsol, A., Heitz, F., Szyndralewiez, C., Page, P., Kennedy, C.R.J., Burns, K.D., Touyz, R.M., Hébert, R.L., Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am. J. Physiol. – Renal Physiol. 299:6 (2010), F1348–F1358.
92. [92] Bondi, C.D., Manickam, N., Lee, D.Y., Block, K., Gorin, Y., Abboud, H.E., Barnes, J.L., NAD(P)H oxidase mediates TGF-β1–induced activation of kidney myofibroblasts. J. Am. Soc. Nephrol.: JASN 21:1 (2010), 93–102.
93. [93] Ismail, S., Sturrock, A., Wu, P., Cahill, B., Norman, K., Huecksteadt, T., Sanders, K., Kennedy, T., Hoidal, J., NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-beta 1 and insulin-like growth factor binding protein-3. Am. J. Physiol. Lung Cell. Mol. Physiol. 296:3 (2009), L489–L499.
94. [94] Michaeloudes, C., Sukkar, M.B., Khorasani, N.M., Bhavsar, P.K., Chung, K.F., TGF-β regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am. J. Physiol. – Lung Cell. Mol. Physiol. 300:2 (2011), L295–L304.
95. [95] Boudreau, H.E., Casterline, B.W., Rada, B., Korzeniowska, A., Leto, T.L., Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic. Biol. Med. 53:7 (2012), 1489–1499.
96. [96] Shono, T., Yokoyama, N., Uesaka, T., Kuroda, J., Takeya, R., Yamasaki, T., Amano, T., Mizoguchi, M., Suzuki, S.O., Niiro, H., Miyamoto, K., Akashi, K., Iwaki, T., Sumimoto, H., Sasaki, T., Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. Int. J. Cancer 123:4 (2008), 787–792.
97. [97] Yamaura, M., Mitsushita, J., Furuta, S., Kiniwa, Y., Ashida, A., Goto, Y., Shang, W.H., Kubodera, M., Kato, M., Takata, M., Saida, T., Kamata, T., NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression. Cancer Res. 69:6 (2009), 2647–2654.
98. [98] Graham, K.A., Kulawiec, M., Owens, K.M., Li, X., Desouki, M.M., Chandra, D., Singh, K.K., NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biol. Ther. 10:3 (2010), 223–231.
99. [99] Zhang, C., Lan, T., Hou, J., Li, J., Fang, R., Yang, Z., Zhang, M., Liu, J., Liu, B., NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling. Oncotarget 5:12 (2014), 4392–4405.
100. [100] Gregg, J.L., Turner, R.M., Chang, G., Joshi, D., Zhan, Y., Chen, L., Maranchie, J.K., NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α. Cancer Res. 74:13 (2014), 3501–3511.
101. [101] Halliwell, B., Biochemistry of oxidative stress. Biochem. Soc. Trans. 35:Pt 5 (2007), 1147–1150.
102. [102] Fuchs-Tarlovsky, V., Role of antioxidants in cancer therapy. Nutrition 29:1 (2013), 15–21.
103. [103] Packer, L., Weber, S.U., Rimbach, G., Molecular aspects of α-tocotrienol antioxidant action and cell signalling. J. Nutr. 131:2 (2001), 369S–373S.
104. [104] Thakur, V., Morley, S., Manor, D., The hepatic alpha tocopherol transfer protein (TTP): ligand-induced protection from proteasomal degradation. Biochemistry 49:43 (2010), 9339–9344.
105. [105] Fiedor, J., Burda, K., Potential role of carotenoids as antioxidants in human health and disease. Nutrients 6:2 (2014), 466–488.
106. [106] Rahmanto, A.S., Davies, M.J., Selenium-containing amino acids as direct and indirect antioxidants. IUBMB Life 64:11 (2012), 863–871.
107. [107] Blot, W.J., Li, J.Y., Taylor, P.R., Guo, W., Dawsey, S., Wang, G.Q., Yang, C.S., Zheng, S.F., Gail, M., Li, G.Y., et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 85:18 (1993), 1483–1492.
108. [108] Klein, E.A., Thompson, I.M. Jr., Tangen, C.M., Crowley, J.J., Lucia, M.S., Goodman, P.J., Minasian, L.M., Ford, L.G., Parnes, H.L., Gaziano, J.M., Karp, D.D., Lieber, M.M., Walther, P.J., Klotz, L., Parsons, J.K., Chin, J.L., Darke, A.K., Lippman, S.M., Goodman, G.E., Meyskens, F.L. Jr., Baker, L.H., Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 306:14 (2011), 1549–1556.
109. [109] Lippman, S.M., Klein, E.A., Goodman, P.J., Lucia, M.S., Thompson, I.M., Ford, L.G., Parnes, H.L., Minasian, L.M., Gaziano, J.M., Hartline, J.A., Parsons, J.K., Bearden, J.D. 3rd, Crawford, E.D., Goodman, G.E., Claudio, J., Winquist, E., Cook, E.D., Karp, D.D., Walther, P., Lieber, M.M., Kristal, A.R., Darke, A.K., Arnold, K.B., Ganz, P.A., Santella, R.M., Albanes, D., Taylor, P.R., Probstfield, J.L., Jagpal, T.J., Crowley, J.J., Meyskens, F.L. Jr., Baker, L.H., Coltman, C.A. Jr., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:1 (2009), 39–51.
110. [110] de la Maza, M.P., Petermann, M., Bunout, D., Hirsch, S., Effects of long-term vitamin E supplementation in alcoholic cirrhotics. J. Am. Coll. Nutr. 14:2 (1995), 192–196.
111. [111] van Zandwijk, N., Dalesio, O., Pastorino, U., de Vries, N., van Tinteren, H., EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European organization for research and treatment of cancer head and neck and lung cancer cooperative groups. J. Natl. Cancer Inst. 92:12 (2000), 977–986.
112. [112] Heinonen, O., Huttunen, J., Albanes, D., The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med. 330:15 (1994), 1029–1035.
113. [113] Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Meyskens, F.L. Jr., Omenn, G.S., Valanis, B., Williams, J.H. Jr., The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J. Natl. Cancer Inst. 96:23 (2004), 1743–1750.
114. [114] Hennekens, C.H., Buring, J.E., Manson, J.E., Stampfer, M., Rosner, B., Cook, N.R., Belanger, C., LaMotte, F., Gaziano, J.M., Ridker, P.M., Willett, W., Peto, R., Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:18 (1996), 1145–1149.
115. [115] Lee, I.M., Cook, N.R., Manson, J.E., Buring, J.E., Hennekens, C.H., Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J. Natl. Cancer Inst. 91:24 (1999), 2102–2106.
116. [116] M.L. Neuhouser, M.J. Barnett, A.R. Kristal, C.B. Ambrosone, I.B. King, M. Thornquist, G.G. Goodman, Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial, Cancer epidemiology, biomarkers and prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive, Oncology 18(8), 2009, 2202-6.
117. [117] Heinonen, O., Huttunen, J., Albanes, D., The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330:15 (1994), 1029–1035.
118. [118] Hajhashemi, V., Vaseghi, G., Pourfarzam, M., Abdollahi, A., Are antioxidants helpful for disease prevention?. Res. Pharm. Sci. 5:1 (2010), 1–8.
119. [119] Chakravarthi, S., Jessop, C.E., Bulleid, N.J., The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress. EMBO Rep. 7:3 (2006), 271–275.
120. [120] Meister, A., Glutathione, ascorbate, and cellular protection. Cancer Res. 54:7 Suppl (1994), 1969s–1975s.
121. [121] Schmitt, B., Vicenzi, M., Garrel, C., Denis, F.M., Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biol. 6 (2015), 198–205.
122. [122] Cook, G.C., Sherlock, S., Results of a controlled clinical trial of glutathione in cases of hepatic cirrhosis. Gut 6:5 (1965), 472–476.
123. [123] Khoshbaten, M., Aliasgarzadeh, A., Masnadi, K., Tarzamani, M.K., Farhang, S., Babaei, H., Kiani, J., Zaare, M., Najafipoor, F., N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. Hepat. Mon. 10:1 (2010), 12–16.
124. [124] T.I.P.F.C.R. Network, Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2093–2101.
125. [125] Behr, J., Demedts, M., Buhl, R., Costabel, U., Dekhuijzen, R.P., Jansen, H.M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A.G., Verbeken, E.K., Verschakelen, J., Flower, C., Petruzzelli, S., De Vuyst, P., Bosch, vdJ., Rodriguez-Becerra, E., Lankhorst, I., Sardina, M., Boissard, G., Lung function in idiopathic pulmonary fibrosis – extended analyses of the IFIGENIA trial. Respir. Res. 10:1 (2009), 1–9.
126. [126] Zhang, H., Forman, H.J., Choi, J., Gamma-glutamyl transpeptidase in glutathione biosynthesis. Methods Enzymol. 401 (2005), 468–483.
127. [127] Hong, S.-Y., Gil, H.-W., Yang, J.-O., Lee, E.-Y., Kim, H.-K., Kim, S.-H., Chung, Y.-H., Lee, E.-M., Hwang, S.-K., Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. Korean J. Intern. Med. 20:3 (2005), 217–223.
128. [128] Martinez, F.J., de Andrade, J.A., Anstrom, K.J., King, T.E. Jr., Raghu, G., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2093–2101.
129. [129] Zhang, H.J., Yan, T., Oberley, T.D., Oberley, L.W., Comparison of effects of two polymorphic variants of manganese superoxide dismutase on human breast MCF-7 cancer cell phenotype. Cancer Res. 59:24 (1999), 6276–6283.
130. [130] Weydert, C.J., Waugh, T.A., Ritchie, J.M., Iyer, K.S., Smith, J.L., Li, L., Spitz, D.R., Oberley, L.W., Overexpression of manganese or copper–zinc superoxide dismutase inhibits breast cancer growth. Free Radic. Biol. Med. 41:2 (2006), 226–237.
131. [131] Zhong, W., Oberley, L.W., Oberley, T.D., St Clair, D.K., Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 14:4 (1997), 481–490.
132. [132] Church, S.L., Grant, J.W., Ridnour, L.A., Oberley, L.W., Swanson, P.E., Meltzer, P.S., Trent, J.M., Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. 90:7 (1993), 3113–3117.
133. [133] Hu, Y., Rosen, D.G., Zhou, Y., Feng, L., Yang, G., Liu, J., Huang, P., Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J. Biol. Chem. 280:47 (2005), 39485–39492.
134. [134] Zhang, Y., Zhao, W., Zhang, H.J., Domann, F.E., Oberley, L.W., Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. Cancer Res. 62:4 (2002), 1205–1212.
135. [135] Epperly, M.W., Carpenter, M., Agarwal, A., Mitra, P., Nie, S., Greenberger, J.S., Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis. In vivo (Athens, Greece) 18:4 (2004), 401–410.
136. [136] Niu, Y., Epperly, M.W., Shen, H., Smith, T., Wang, H., Greenberger, J.S., Intraesophageal MnSOD-plasmid liposome enhances engraftment and self-renewal of bone marrow derived progenitors of esophageal squamous epithelium. Gene Ther. 15:5 (2007), 347–356.
137. [137] Tarhini, A.A., Belani, C.P., Luketich, J.D., Argiris, A., Ramalingam, S.S., Gooding, W., Pennathur, A., Petro, D., Kane, K., Liggitt, D., ChampionSmith, T., Zhang, X., Epperly, M.W., Greenberger, J.S., A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer. Hum. Gene Ther. 22:3 (2011), 336–342.
138. [138] Campana, F., Zervoudis, S., Perdereau, B., Gez, E., Fourquet, A., Badiu, C., Tsakiris, G., Koulaloglou, S., Topical superoxide dismutase reduces post-irradiation breast cancer fibrosis. J. Cell. Mol. Med. 8:1 (2004), 109–116.
139. [139] Apeiron, Press Release: Positive Outcome in Clinical Study to Prevent Radiation-induced Dermatitis in Breast Cancer Patients, Vienna, Austria, 2013.
140. [140] Thomas, R., Sharifi, N., SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer. Mol. Cancer Ther. 11:1 (2012), 87–97.
141. [141] Shah, M.H., Liu, G.-S., Thompson, E.W., Dusting, G.J., Peshavariya, H.M., Differential effects of superoxide dismutase and superoxide dismutase/catalase mimetics on human breast cancer cells. Breast Cancer Res. Treat. 150:3 (2015), 523–534.
142. [142] Yan, S., Liu, G., Pei, C., Chen, W., Li, P., Wang, Q., Jin, X., Zhu, J., Wang, M., Liu, X., Inhibition of NADPH oxidase protects against metastasis of human lung cancer by decreasing microRNA-21. AntiCancer Drugs 26:4 (2015), 388–398.
143. [143] Dosoki, H., Stegemann, A., Taha, M., Schnittler, H., Luger, T.A., Schroder, K., Distler, J.H., Kerkhoff, C., Bohm, M., Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Exp. Dermatol., 2016.
144. [144] S.S.Bhandarkar, M.Jaconi, L.E.Fried, M.Y.Bonner, B.Lefkove, B.Govindarajan, B.N.Perry, R.Parhar, J.Mackelfresh, A.Sohn, M.Stouffs, U.Knaus, G.Yancopoulos, Y.Reiss, A.V.Benest, H.G.Augustin, J.L.Arbiser, Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice, J. Clin. Investig., 119(8), pp. 2359–2365.
145. [145] Jaquet, V., Marcoux, J., Forest, E., Leidal, K.G., McCormick, S., Westermaier, Y., Perozzo, R., Plastre, O., Fioraso-Cartier, L., Diebold, B., Scapozza, L., Nauseef, W.M., Fieschi, F., Krause, K.H., Bedard, K., NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action. Br. J. Pharmacol. 164:2b (2011), 507–520.
146. [146] Zhu, H., Liu, X.-W., Cai, T.-Y., Cao, J., Tu, C.-X., Lu, W., He, Q.-J., Yang, B., Celastrol acts as a potent antimetastatic agent targeting β1 integrin and inhibiting cell-extracellular matrix adhesion, in Part via the p38 mitogen-activated protein kinase pathway. J. Pharmacol. Exp. Ther. 334:2 (2010), 489–499.
147. [147] Jiang, J.X., Chen, X., Serizawa, N., Szyndralewiez, C., Page, P., Schroder, K., Brandes, R.P., Devaraj, S., Torok, N.J., Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic. Biol. Med. 53:2 (2012), 289–296.
148. [148] Cifuentes-Pagano, E., Meijles, D.N., Pagano, P.J., The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls. Antioxid. Redox Signal. 20:17 (2014), 2741–2754.
149. [149] Crosas-Molist, E., Bertran, E., Sancho, P., López-Luque, J., Fernando, J., Sánchez, A., Fernández, M., Navarro, E., Fabregat, I., The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression. Free Radic. Biol. Med. 69 (2014), 338–347.
150. [150] Wind, S., Beuerlein, K., Eucker, T., Müller, H., Scheurer, P., Armitage, M.E., Ho, H., Schmidt, H., Wingler, K., Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. 161:4 (2010), 885–898.
151. [151] Dong, K.R., Zheng, S., Xiao, X., Conservative management of neonatal hepatic hemangioma: a report from one institute. Pediatr. Surg. Int. 25:6 (2009), 493–498.
152. [152] Munson, J.M., Fried, L., Rowson, S.A., Bonner, M.Y., Karumbaiah, L., Diaz, B., Courtneidge, S.A., Knaus, U.G., Brat, D.J., Arbiser, J.L., Bellamkonda, R.V., Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci. Transl. Med., 4(127), 2012 127ra36-127ra36.
153. [153] Yang, W.H., Su, Y.H., Hsu, W.H., Wang, C.C., Arbiser, J.L., Yang, M.H., Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation. Oncogene 35:18 (2016), 2287–2298.
154. [154] Garrido-Urbani, S., Jemelin, S., Deffert, C., Carnesecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., Michalik, L., Arbiser, J., Rüegg, C., Krause, K.H., Imhof, B., Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism. PLoS One, 6(2), 2011, e14665.
155. [155] Das, S., Dowding, J.M., Klump, K.E., McGinnis, J.F., Self, W., Seal, S., Cerium oxide nanoparticles: applications and prospects in nanomedicine. Nanomedicine (Lond. Engl.) 8:9 (2013), 1483–1508.
156. [156] Giri, S., Karakoti, A., Graham, R.P., Maguire, J.L., Reilly, C.M., Seal, S., Rattan, R., Shridhar, V., Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian. Cancer PLoS One, 8(1), 2013, e54578.
157. [157] Hijaz, M., Das, S., Mert, I., Gupta, A., Al-Wahab, Z., Tebbe, C., Dar, S., Chhina, J., Giri, S., Munkarah, A., Seal, S., Rattan, R., Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer. BMC Cancer, 16, 2016, 220.
158. [158] Siu, K.S., Chen, D., Zheng, X., Zhang, X., Johnston, N., Liu, Y., Yuan, K., Koropatnick, J., Gillies, E.R., Min, W.P., Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma. Biomaterials 35:10 (2014), 3435–3442.
159. [159] Hirst, S.M., Karakoti, A., Singh, S., Self, W., Tyler, R., Seal, S., Reilly, C.M., Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ. Toxicol. 28:2 (2013), 107–118.
160. [160] Grebowski, J., Krokosz, A., Fullerenes in radiobiology. Post. Biochem. 56:4 (2010), 456–462.
161. [161] Andrievsky, G.V., Bruskov, V.I., Tykhomyrov, A.A., Gudkov, S.V., Peculiarities of the antioxidant and radioprotective effects of hydrated C60 fullerene nanostuctures in vitro and in vivo. Free Radic. Biol. Med. 47:6 (2009), 786–793.
162. [162] Xu, J.-Y., Su, Y.-Y., Cheng, J.-S., Li, S.-X., Liu, R., Li, W.-X., Xu, G.-T., Li, Q.-N., Protective effects of fullerenol on carbon tetrachloride-induced acute hepatotoxicity and nephrotoxicity in rats. Carbon 48:5 (2010), 1388–1396.
163. [163] Prylutska, S., Grynyuk, I., Matyshevska, O., Prylutskyy, Y., Evstigneev, M., Scharff, P., Ritter, U., C(60) fullerene as synergistic agent in tumor-inhibitory doxorubicin treatment. Drugs R&D 14:4 (2014), 333–340.
164. [164] Katsumi, H., Fukui, K., Sato, K., Maruyama, S., Yamashita, S., Mizumoto, E., Kusamori, K., Oyama, M., Sano, M., Sakane, T., Yamamoto, A., Pharmacokinetics and preventive effects of platinum nanoparticles as reactive oxygen species scavengers on hepatic ischemia/reperfusion injury in mice. Metallomics 6:5 (2014), 1050–1056.
165. [165] Shibuya, S., Ozawa, Y., Watanabe, K., Izuo, N., Toda, T., Yokote, K., Shimizu, T., Palladium and platinum nanoparticles attenuate aging-like skin atrophy via antioxidant activity in mice. PLoS One, 9(10), 2014, e109288.
166. [166] Yoshihisa, Y., Honda, A., Zhao, Q.L., Makino, T., Abe, R., Matsui, K., Shimizu, H., Miyamoto, Y., Kondo, T., Shimizu, T., Protective effects of platinum nanoparticles against UV-light-induced epidermal inflammation. Exp. Dermatol. 19:11 (2010), 1000–1006.
167. [167] Hao, N., Yang, H., Li, L., Li, L., Tang, F., The shape effect of mesoporous silica nanoparticles on intracellular reactive oxygen species in A375 cells. N. J. Chem. 38:9 (2014), 4258–4266.
168. [168] Huang, X., Zhuang, J., Teng, X., Li, L., Chen, D., Yan, X., Tang, F., The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials 31:24 (2010), 6142–6153.
169. [169] Morry, J., Ngamcherdtrakul, W., Gu, S., Goodyear, S.M., Castro, D.J., Reda, M.M., Sangvanich, T., Yantasee, W., Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. Biomaterials 66 (2015), 41–52.
170. [170] Slowing, I.I., Trewyn, B.G., Giri, S., Lin, V.S.Y., Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv. Funct. Mater. 17:8 (2007), 1225–1236.
171. [171] Tarn, D., Ashley, C.E., Xue, M., Carnes, E.C., Zink, J.I., Brinker, C.J., Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc. Chem. Res. 46:3 (2013), 792–801.
172. [172] Trewyn, B.G., Nieweg, J.A., Zhao, Y., Lin, V.S.Y., Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration. Chem. Eng. J. 137:1 (2008), 23–29.
173. [173] Ngamcherdtrakul, W., Morry, J., Gu, S., Castro, D.J., Goodyear, S.M., Sangvanich, T., Reda, M.M., Lee, R., Mihelic, S.A., Beckman, B.L., Hu, Z., Gray, J.W., Yantasee, W., Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv. Funct. Mater. 25:18 (2015), 2646–2659.
174. [174] He, Q., Zhang, Z., Gao, F., Li, Y., Shi, J., In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 7:2 (2011), 271–280.
175. [175] Kumar, R., Roy, I., Ohulchanskky, T.Y., Vathy, L.A., Bergey, E.J., Sajjad, M., Prasad, P.N., In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano 4:2 (2010), 699–708.
176. [176] Lee, J.-A., Kim, M.-K., Paek, H.-J., Kim, Y.-R., Kim, M.-K., Lee, J.-K., Jeong, J., Choi, S.-J., Tissue distribution and excretion kinetics of orally administered silica nanoparticles in rats. Int. J. Nanomed. 9:Suppl. 2 (2014), 251–260.
177. [177] Phillips, E., Penate-Medina, O., Zanzonico, P.B., Carvajal, R.D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., Strauss, H.W., Larson, S.M., Wiesner, U., Bradbury, M.S., Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med., 6(260), 2014, 260ra149.
178. [178] Ishida, Y., Nagata, K., Hsp47 as a collagen-specific molecular chaperone. Methods Enzymol. 499 (2011), 167–182.
179. [179] Ngamcherdtrakul, W., Castro, D.J., Gu, S., Morry, J., Reda, M., Gray, J.W., Yantasee, W., Current development of targeted oligonucleotide-based cancer therapies: perspective on HER2-positive breast cancer treatment. Cancer Treat. Rev. 45 (2016), 19–29.